| Patient | Rachel Carson |
|---|---|
| Date of birth | 1973-05-27 |
| Identifiers | MRN HR-ML041-SYN; SSN (made up) 000-41-5068 |
| Document date | 2026-06-15 |
| Author | Margaret Vance-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Start of letrozole, ribociclib, and zoledronic acid after radiation. [S]
Ms. Carson completed whole-breast and regional nodal radiation with a tumor-bed boost two and a half weeks ago, in 19 afternoon sessions, with mild reddening of the skin that has faded. She kept writing in the mornings throughout. Her dental check last week was normal. Today she starts letrozole and the first 28-day cycle of ribociclib, and has her first zoledronic acid infusion. She has read the side-effect sheets and asked for the monitoring schedule in writing, which she was given. She has mild morning knee stiffness, unchanged, and no hot flashes. She takes no other medicines and no grapefruit or herbal products. [S]
| Element | Detail |
|---|---|
| Interval change | Radiation completed two and a half weeks ago |
| Skin | Grade 1 reddening, now faded |
| Today | Letrozole and ribociclib cycle 1 day 1; first zoledronic acid infusion |
| Dental | Dental check last week normal |
| Interactions | No QT-prolonging drugs, strong CYP3A inhibitors, grapefruit, or herbal products |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild tiredness after radiation, improving |
| Integumentary | Negative | Radiation reddening faded; no blistering |
| Cardiovascular | Negative | No palpitations, fainting, or chest pain |
| Musculoskeletal | Positive | Mild morning knee stiffness, baseline before letrozole; no bone pain |
| Genitourinary | Negative | No vaginal dryness or bleeding |
| Psychiatric | Negative | Mood steady |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healing | One capsule once daily before breakfast | Oral route | 2026-01-19 to 2026-04-03 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2025-06-02 | active | S |
| Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years | Two tablets once daily on days 1 to 21 of each 28-day cycle | Oral route | 2026-06-15 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years | One infusion every six months | Intravenous route | 2026-06-15 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-15 | Body height | 163 | cm | S |
| 2026-06-15 | Body weight | 58.9 | kg | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 2026-06-15 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-06-15 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-15 | Heart rate | 70 | /min | S |
| 2026-06-15 | Respiratory rate | 14 | /min | S |
| 2026-06-15 | Body temperature | 36.6 | Cel | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-15 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-15 | Leukocytes [#/volume] in Blood by Automated count | 5.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-15 | Neutrophils [#/volume] in Blood by Automated count | 3.4 | 10*3/uL | 1.8-7.7 10*3/uL | Normal | S |
| 2026-06-15 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-06-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | <=33 U/L | Normal | S |
| 2026-06-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | <=32 U/L | Normal | S |
| 2026-06-15 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | <=1.2 mg/dL | Normal | S |
| 2026-06-15 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-15 | Magnesium [Mass/volume] in Serum or Plasma | 2.1 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| 2026-06-15 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-06-15 | Cholesterol [Mass/volume] in Serum or Plasma | 208 | mg/dL | <=199 mg/dL | High | S |
| 2026-06-15 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 62 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-06-15 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 124 | mg/dL | <=99 mg/dL | High | S |
| 2026-06-15 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-06-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 2026-06-15 | Q-T interval corrected | 418 | ms | Ribociclib is started only when QTcF is below 450 ms | Normal | S |
| 2026-06-15 | DXA Lumbar spine [T-score] Bone density | -1.8 | {T-score} | >=-1 | Low | S |
| 2026-06-15 | DXA Femur [T-score] Bone density | -1.3 | {T-score} | >=-1 | Low | S |
Vital signs recorded on 2026-06-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Breasts | Left breast with faint tanning and mild firmness after radiation; scar healed; no masses. Right breast normal |
| Lymph nodes | No axillary or supraclavicular nodes |
| Extremities | Arm circumference 25.5 cm on each side; full shoulder movement; knees with mild crepitus, no effusion |
| Mouth | Teeth and gums in good repair |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1960 breast cancer, which was not disclosed to her | active | confirmed | C50.412 | S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy booked | resolved | confirmed | N63.21 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D). |
| Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure planned | resolved | confirmed | K26.9 | S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date. |
| Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shore | active | confirmed | M17.0 | S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private. |
| Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17 | active | confirmed | C77.3 | S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used. |
| Long-term use of letrozole as adjuvant endocrine therapy, with ribociclib for three years | active | confirmed | Z79.811 | S — Synthetic treatment status. |
| Low bone mass (osteopenia) on baseline DXA before letrozole: lumbar spine T-score -1.8, femoral neck -1.3; 10-year major osteoporotic fracture risk about 7 percent (FRAX); vitamin D insufficiency | active | confirmed | M85.80 | S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | ECG before ribociclib | Before the first dose; start only if QTcF is below 450 ms | Completed today | QTcF 418 ms, sinus rhythm 70/min |
| Laboratory | Blood count before ribociclib | Before the first dose, then every 2 weeks for 2 cycles | Completed today | White cells 5.9, neutrophils 3.4, hemoglobin 12.8, platelets 240 |
| Laboratory | Liver tests before ribociclib | Before the first dose, then every 2 weeks for 2 cycles | Completed today | ALT 20, AST 22, bilirubin 0.6 |
| Laboratory | Electrolytes before ribociclib | Before the first dose and at the start of each of the first 6 cycles | Completed today | Potassium 4.2, magnesium 2.1, calcium 9.4 |
| Medication safety | Interaction review: QT-prolonging drugs and strong CYP3A inhibitors | At the start and with every new medicine | Completed today | None taken; written list given |
| Medication safety | ECG at about day 14 of the first cycle | Day 14 of cycle 1 | Due | Booked with the day-14 blood tests |
| Medication safety | Aromatase inhibitor start | At initiation | Completed today | Letrozole 2.5 mg daily; postmenopausal for two years, so no ovarian suppression needed |
| Imaging | Bone density (DXA) | Baseline at aromatase inhibitor start, then every 2 years | Completed today | Lumbar spine T-score -1.8, femoral neck -1.3: low bone mass |
| Medication safety | Zoledronic acid: kidney function, calcium, and dental check | Before each infusion | Completed today | Creatinine 0.8, eGFR 87, calcium 9.4; dental check normal; first infusion today |
| Laboratory | Calcium and vitamin D adequacy | Ongoing on an aromatase inhibitor | Completed today | 25-hydroxyvitamin D 22 ng/mL, insufficient; vitamin D3 started |
| Laboratory | Lipid panel | Periodically on an aromatase inhibitor, by cardiovascular risk | Completed today | Total cholesterol 208, HDL 62, LDL 124, triglycerides 110 mg/dL |
| Examination | Aromatase inhibitor joint pain and musculoskeletal review | Every visit | Completed today | Baseline: mild knee stiffness from osteoarthritis |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | 25.5 cm on each side; no swelling after nodal radiation |
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No signs of recurrence |
| Imaging | Mammogram after breast-conserving treatment | 6 to 12 months after radiation, then yearly | Due | Between six and twelve months after radiation |
| Self-management | Written monitoring schedule and survivorship care plan | At the start of adjuvant therapy | Completed today | Monitoring calendar and treatment summary given; 150 minutes of activity a week; alcohol at or below one drink a day |
Goal progress:
Guideline basis: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026); Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Oncology ECG and blood tests at about day 14. Sick visits through the oncology nurse line for fever. Primary care monitoring visit at the start of the fourth cycle. Next scheduled visit 2026-09-08: monitoring visit at the start of the fourth ribociclib cycle. [S]